Amendment AA2-ASA2-AB68

AB68-ASA2-AA2,84,17 6. Genetic information.

AB68-ASA2-AA2,84,19 7. Evidence of insurability, including conditions arising out of acts of domestic violence.

AB68-ASA2-AA2,84,20 8. Disability.

AB68-ASA2-AA2,85,2 (b) A short-term, limited duration plan may not require any individual, as a condition of enrollment or continued enrollment under the plan, to pay, on the basis of any health status-related factor under par. (a) with respect to the individual or a dependent of the individual, a premium or contribution or a deductible, copayment, or coinsurance amount that is greater than the premium or contribution or deductible, copayment, or coinsurance amount respectively for a similarly situated individual enrolled under the plan.

AB68-ASA2-AA2,85,4 (4) Premium rate variation. A short-term, limited duration plan may vary premium rates for a specific plan based only on the following considerations:

AB68-ASA2-AA2,85,5 (a) Whether the policy or plan covers an individual or a family.

AB68-ASA2-AA2,85,6 (b) Rating area in the state, as established by the commissioner.

AB68-ASA2-AA2,85,9 (c) Age, except that the rate may not vary by more than 3 to 1 for adults over the age groups and the age bands shall be consistent with recommendations of the National Association of Insurance Commissioners.

AB68-ASA2-AA2,85,10 (d) Tobacco use, except that the rate may not vary by more than 1.5 to 1.

AB68-ASA2-AA2,85,12 (5) Annual and lifetime limits. A short-term, limited duration plan may not establish any of the following:

AB68-ASA2-AA2,85,14 (a) Lifetime limits on the dollar value of benefits for an enrollee or a dependent of an enrollee under the plan.

AB68-ASA2-AA2,85,16 (b) Limits on the dollar value of benefits for an enrollee or a dependent of an enrollee under the plan for the initial or cumulative duration of the plan.

AB68-ASA2-AA2,412yj Section 412yj. 632.76 (2) (a) and (ac) 1. and 2. of the statutes are amended to read:

AB68-ASA2-AA2,86,2 632.76 (2) (a) No claim for loss incurred or disability commencing after 2 years from the date of issue of the policy may be reduced or denied on the ground that a disease or physical condition existed prior to the effective date of coverage, unless the condition was excluded from coverage by name or specific description by a provision effective on the date of loss. This paragraph does not apply to a group health benefit plan, as defined in s. 632.745 (9), which is subject to s. 632.746 , a disability insurance policy, as defined in s. 632.895 (1) (a), or a self-insured health plan, as defined in s. 632.85 (1) (c).

AB68-ASA2-AA2,86,8 (ac) 1. Notwithstanding par. (a), no No claim or loss incurred or disability commencing after 12 months from the date of issue of under an individual disability insurance policy, as defined in s. 632.895 (1) (a), may be reduced or denied on the ground that a disease or physical condition existed prior to the effective date of coverage, unless the condition was excluded from coverage by name or specific description by a provision effective on the date of the loss.

AB68-ASA2-AA2,86,15 2. Except as provided in subd. 3., an An individual disability insurance policy, as defined in s. 632.895 (1) (a), other than a short-term policy subject to s. 632.7495 (4) and (5), may not define a preexisting condition more restrictively than a condition that was present before the date of enrollment for the coverage, whether physical or mental, regardless of the cause of the condition, for which and regardless of whether medical advice, diagnosis, care, or treatment was recommended or received within 12 months before the effective date of coverage.

AB68-ASA2-AA2,412ym Section 412ym. 632.76 (2) (ac) 3. (intro.) of the statutes is amended to read:

AB68-ASA2-AA2,86,19 632.76 (2) (ac) 3. (intro.) Except as the commissioner provides by rule under s. 632.7495 (5), all of the following apply to an individual disability insurance policy that is a short-term, limited duration policy subject to s. 632.7495 (4) and (5):

AB68-ASA2-AA2,412yp Section 412yp. 632.76 (2) (ac) 3. b. of the statutes is amended to read:

AB68-ASA2-AA2,87,2 632.76 (2) (ac) 3. b. The policy shall reduce the length of time during which a may not impose any preexisting condition exclusion may be imposed by the aggregate of the insured's consecutive periods of coverage under the insurer's individual disability insurance policies that are short-term policies subject to s. 632.7495 (4) and (5). For purposes of this subd. 3. b., coverage periods are consecutive if there are no more than 63 days between the coverage periods.

AB68-ASA2-AA2,412ys Section 412ys. 632.795 (4) (a) of the statutes is amended to read:

AB68-ASA2-AA2,87,15 632.795 (4) (a) An insurer subject to sub. (2) shall provide coverage under the same policy form and for the same premium as it originally offered in the most recent enrollment period, subject only to the medical underwriting used in that enrollment period. Unless otherwise prescribed by rule, the insurer may apply deductibles, preexisting condition limitations, waiting periods , or other limits only to the extent that they would have been applicable had coverage been extended at the time of the most recent enrollment period and with credit for the satisfaction or partial satisfaction of similar provisions under the liquidated insurer's policy or plan. The insurer may exclude coverage of claims that are payable by a solvent insurer under insolvency coverage required by the commissioner or by the insurance regulator of another jurisdiction. Coverage shall be effective on the date that the liquidated insurer's coverage terminates.

AB68-ASA2-AA2,412yu Section 412yu. 632.796 of the statutes is created to read:

AB68-ASA2-AA2,87,18 632.796 Drug cost report. (1) Definition. In this section, “disability insurance policy” has the meaning given in s. 632.895 (1) (a).

AB68-ASA2-AA2,87,24 (2) Report required. Annually, at the time the insurer files its rate request with the commissioner, each insurer that offers a disability insurance policy that covers prescription drugs shall submit to the commissioner a report that identifies the 25 prescription drugs that are the highest cost to the insurer and the 25 prescription drugs that have the highest cost increases over the 12 months before the submission of the report.

AB68-ASA2-AA2,412yw Section 412yw. 632.862 of the statutes is created to read:

AB68-ASA2-AA2,88,2 632.862 Application of prescription drug payments. (1) Definitions. In this section:

AB68-ASA2-AA2,88,3 (a) “Brand name” has the meaning given in s. 450.12 (1) (a).

AB68-ASA2-AA2,88,4 (b) “Brand name drug” means any of the following:

AB68-ASA2-AA2,88,6 1. A prescription drug that contains a brand name and that has no generic equivalent.

AB68-ASA2-AA2,88,10 2. A prescription drug that contains a brand name and has a generic equivalent but for which the enrollee has received prior authorization from the insurer offering the disability insurance policy or the self-insured health plan or authorization from a physician to obtain the prescription drug under the policy or plan.

AB68-ASA2-AA2,88,11 (c) “Disability insurance policy” has the meaning given in s. 632.895 (1) (a).

AB68-ASA2-AA2,88,12 (d) “Prescription drug” has the meaning given in s. 450.01 (20)

AB68-ASA2-AA2,88,13 (e) “Self-insured health plan” has the meaning given in s. 632.85 (1) (c).

AB68-ASA2-AA2,88,19 (2) Application of discounts. A disability insurance policy that offers a prescription drug benefit or a self-insured health plan shall apply to any calculation of an out-of-pocket maximum and to any deductible of the policy or plan for an enrollee the amount that any discount provided by the manufacturer of a brand name drug reduces the cost sharing amount charged to an enrollee for that brand name drug.

AB68-ASA2-AA2,412yz Section 412yz. 632.8655 of the statutes is created to read:

AB68-ASA2-AA2,88,22 632.8655 Prescription drug cost reporting. (1) Definitions. In this section:

AB68-ASA2-AA2,88,24 (a) “Brand-name drug” means a prescription drug approved under 21 USC 355 (b) or 42 USC 262.

AB68-ASA2-AA2,89,2 (b) “Covered hospital” means an entity described in 42 USC 256b (a) (4) (L) to (N) that participates in the federal drug pricing program under 42 USC 256b.

AB68-ASA2-AA2,89,3 (c) “Generic drug” means a prescription drug approved under 21 USC 355 (j).

AB68-ASA2-AA2,89,7 (d) “Margin” means, for a covered hospital, the difference between the net cost of a brand-name drug or generic drug covered under the federal drug pricing program under 42 USC 256b and the net payment by the covered hospital for that brand-name drug or generic drug.

AB68-ASA2-AA2,89,9 (e) “Net payment” means the amount paid for a brand-name drug or generic drug after all discounts and rebates have been applied.

AB68-ASA2-AA2,89,14 (2) Hospital margin spending. By March 1 annually, each covered hospital operating in this state shall report to the commissioner the per unit margin for each drug covered under the federal drug pricing program under 42 USC 256b dispensed in the previous year multiplied by the number of units dispensed at that margin and how the margin revenue was used.

AB68-ASA2-AA2,89,20 (3) Public reporting. The commissioner shall publicly post covered hospital documentation of how each hospital spends the margin revenue. The commissioner shall analyze data collected under this section and publish annually a report including an analysis on hospital-specific margins and how that revenue is spent or allocated on a hospital-specific basis. The commissioner shall keep any trade secret or proprietary information confidential.

AB68-ASA2-AA2,412z Section 412z. 632.8665 of the statutes is created to read:

AB68-ASA2-AA2,89,23 632.8665 Prescription drug cost reporting. (1) Definitions. In this section:

AB68-ASA2-AA2,89,25 (a) “Brand-name drug” means a prescription drug approved under 21 USC 355 (b) or 42 USC 262.

AB68-ASA2-AA2,90,1 (b) “Generic drug” means a prescription drug approved under 21 USC 355 (j).

AB68-ASA2-AA2,90,4 (c) “Manufacturer” has the meaning given in s. 450.01 (12). “Manufacturer” does not include an entity that is engaged only in the dispensing, as defined in s. 450.01 (7), of a brand-name drug or generic drug.

AB68-ASA2-AA2,90,8 (d) “Manufacturer-sponsored assistance program” means a program offered by a manufacturer or an intermediary under contract with a manufacturer through which a brand-name drug or generic drug is provided to a patient at no charge or at a discount.

AB68-ASA2-AA2,90,9 (e) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).

AB68-ASA2-AA2,90,13 (f) “Pharmacy services administrative organization” means an entity that provides contracting and other administrative services to a pharmacy to assist the pharmacy in interactions with a 3rd-party payer, pharmacy benefit manager, wholesale drug distributor, or other entity.

AB68-ASA2-AA2,90,17 (g) “Wholesale acquisition cost” means the most recently reported manufacturer list or catalog price for a brand-name drug or generic drug available to wholesalers or direct purchasers in the United States, before application of discounts, rebates, or reductions in price.

AB68-ASA2-AA2,90,23 (2) Price increase or introduction notice; justification report. (a) A manufacturer shall notify the commissioner if it is increasing the wholesale acquisition cost of a brand-name drug on the market in this state by more than 10 percent or by more than $10,000 during any 12-month period or if it intends to introduce to market in this state a brand-name drug that has an annual wholesale acquisition cost of $30,000 or more.

AB68-ASA2-AA2,91,2 (b) A manufacturer shall notify the commissioner if it is increasing the wholesale acquisition cost of a generic drug by more than 25 percent or by more than $300 during any 12-month period or if it intends to introduce to market a generic drug that has an annual wholesale acquisition cost of $3,000 or more.

AB68-ASA2-AA2,91,8 (c) The manufacturer shall provide the notice under par. (a) or (b) in writing at least 30 days before the planned effective date of the cost increase or drug introduction with a justification that includes all documents and research related to the manufacturer's selection of the cost increase or introduction price and a description of life cycle management, market competition and context, and estimated value or cost-effectiveness of the product.

AB68-ASA2-AA2,91,12 (3) Net prices paid by pharmacy benefit managers. By March 1 annually, the manufacturer shall report to the commissioner the value of price concessions, expressed as a percentage of the wholesale acquisition cost, provided to each pharmacy benefit manager for each drug sold in this state.

AB68-ASA2-AA2,91,17 (4) Rebates and price concessions. By March 1 annually, each pharmacy benefit manager shall report to the commissioner the amount received from manufacturers as drug rebates and the value of price concessions, expressed as a percentage of the wholesale acquisition cost, provided by manufacturers for each drug.

AB68-ASA2-AA2,91,21 (5) Manufacturer-sponsored assistance programs. By March 1 annually, each manufacturer shall provide the commissioner with a description of each manufacturer-sponsored patient assistance program in effect during the previous year that includes all of the following:

AB68-ASA2-AA2,91,22 (a) The terms of the programs.

AB68-ASA2-AA2,91,23 (b) The number of prescriptions provided to state residents under the program.

AB68-ASA2-AA2,91,25 (c) The total market value of assistance provided to residents of this state under the program.

AB68-ASA2-AA2,92,3 (6) Pharmacy services administrative organizations. By March 1 annually, each pharmacy services administrative organization shall report to the commissioner all of the following information:

AB68-ASA2-AA2,92,5 (a) The negotiated reimbursement rate of the 25 prescription drugs with the highest reimbursement rates during the previous year.

AB68-ASA2-AA2,92,7 (b) The 25 prescription drugs with the highest year-to-year change in reimbursement rate for the previous year.

AB68-ASA2-AA2,92,8 (c) The schedule of fees charged by the organization to pharmacies.

AB68-ASA2-AA2,92,14 (7) Certification and penalties for noncompliance. Each manufacturer and pharmacy services administrative organization that is required to report under this section shall certify each report as accurate under the penalty of perjury. A manufacturer or pharmacy services administrative organization that fails to submit a report required under this section is subject to a forfeiture of no more than $10,000 each day the report is overdue.

AB68-ASA2-AA2,92,17 (8) Hearing and public reporting. (a) The commissioner shall publicly post manufacturer price justification documents. The commissioner shall keep any trade secret or proprietary information confidential.

AB68-ASA2-AA2,92,23 (b) The commissioner shall analyze data collected under this section and publish annually a report on emerging trends in prescription prices and price increases and shall annually conduct a public hearing based on the analysis under this paragraph. The report under this paragraph shall include analysis of manufacturer prices and price increases and analysis of how pharmacy benefit manager discounts and net costs compare to retail prices paid by patients.

AB68-ASA2-AA2,412zc Section 412zc. 632.868 of the statutes is created to read:

AB68-ASA2-AA2,92,25 632.868 Insulin safety net programs. (1) Definitions. In this section:

AB68-ASA2-AA2,93,2 (a) “Manufacturer" means a person engaged in the manufacturing of insulin that is self-administered on an outpatient basis.

AB68-ASA2-AA2,93,3 (b) “Navigator" has the meaning given in s. 628.90 (3).

AB68-ASA2-AA2,93,5 (c) “Patient assistance program” means a program established by a manufacturer under sub. (3) (a).

AB68-ASA2-AA2,93,6 (d) “Pharmacy" means an entity licensed under s. 450.06 or 450.065.

AB68-ASA2-AA2,93,9 (e) “Urgent need of insulin" means having less than a 7-day supply of insulin readily available for use and needing insulin in order to avoid the likelihood of suffering a significant health consequence.

AB68-ASA2-AA2,93,11 (f) “Urgent need safety net program” means a program established by a manufacturer under sub. (2) (a).

AB68-ASA2-AA2,93,15 (2) Urgent need safety net program. (a) Establishment of program. No later than July 1, 2022, each manufacturer shall establish an urgent need safety net program to make insulin available in accordance with this subsection to individuals who meet the eligibility requirements under par. (b).

AB68-ASA2-AA2,93,17 (b) Eligible individual. An individual shall be eligible to receive insulin under an urgent need safety net program if all of the following conditions are met:

AB68-ASA2-AA2,93,18 1. The individual is in urgent need of insulin.

AB68-ASA2-AA2,93,19 2. The individual is a resident of this state.

AB68-ASA2-AA2,93,20 3. The individual is not receiving public assistance under ch. 49.

AB68-ASA2-AA2,93,25 4. The individual is not enrolled in prescription drug coverage through an individual or group health plan that limits the total cost sharing amount, including copayments, deductibles, and coinsurance, that an enrollee is required to pay for a 30-day supply of insulin to no more than $75, regardless of the type or amount of insulin prescribed.

AB68-ASA2-AA2,94,2 5. The individual has not received insulin under an urgent need safety net program within the previous 12 months, except as allowed under par. (d).

AB68-ASA2-AA2,94,6 (c) Provision of insulin under an urgent need safety net program. 1. In order to receive insulin under an urgent need safety net program, an individual who meets the eligibility requirements under par. (b) shall provide a pharmacy with all of the following:

AB68-ASA2-AA2,94,10 a. A completed application, on a form prescribed by the commissioner that shall include an attestation by the individual, or the individual's parent or legal guardian if the individual is under the age of 18, that the individual meets all of the eligibility requirements under par. (b).

AB68-ASA2-AA2,94,11 b. A valid insulin prescription.

AB68-ASA2-AA2,94,14 c. A valid Wisconsin driver's license or state identification card. If the individual is under the age of 18, the individual's parent or legal guardian shall meet this requirement.

AB68-ASA2-AA2,94,22 2. Upon receipt of the information described in subd. 1. a. to c., the pharmacist shall dispense a 30-day supply of the prescribed insulin to the individual. The pharmacy shall also provide the individual with the information sheet described in sub. (8) (b) 2. and the list of navigators described in sub. (8) (c). The pharmacy may collect a copayment, not to exceed $35, from the individual to cover the pharmacy's costs of processing and dispensing the insulin. The pharmacy shall notify the health care practitioner who issued the prescription no later than 72 hours after the insulin is dispensed.